Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.71 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.71 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.71 |
| ▸ | SCD | O00767 | 3/20 | 0.63 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.63 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.63 |
| ▸ | CHEK2 | O96017 | 7/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2807193 | 0.88 | CHEK2 (0.73) | SIRT2SIRT1SIRT3PKN1PKN2 | |
| SCHEMBL2315701 | 0.86 | SCD (0.56) | SIRT2SIRT1SIRT3SCDCHEK2 | |
| SCHEMBL2804499 | 0.86 | SCD (0.64) | SIRT2SIRT1SIRT3SCDPKN1 | |
| SCHEMBL2316764 | 0.86 | CHEK2 (0.77) | SCDCHEK2 | |
| SCHEMBL2357098 | 0.80 | CHEK2 (0.74) | SIRT2SIRT1SIRT3PKN1PKN2 | |
| SCHEMBL2316768 | 0.80 | SCD (0.59) | SCDCHEK2 | |
| SCHEMBL19994531 | 0.79 | SIRT2 (0.79) | SIRT2SIRT1SIRT3PKN1PKN2 | |
| SCHEMBL19994427 | 0.78 | PKN1 (1.00) | SIRT2SIRT1SIRT3PKN1PKN2 | |
| SCHEMBL27002575 | 0.78 | PKN1 (1.00) | SIRT2SIRT1SIRT3PKN1PKN2 | |
| SCHEMBL2804319 | 0.77 | CHEK2 (0.59) | CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240580-A1 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240580-A1 | AZOLOARINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND THE USE THEREOF | CYP3A43, CYP11B1, CYP11B2 | SIRT2 2363/4885SIRT1 1509/4885SIRT3 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.